Baidu
map

Blood:序贯输注CAR19/22 T细胞治疗B细胞恶性肿瘤,有效减少抗原逃逸复发

2019-11-01 一刀 MedSci原创

抗原逃逸复发已成为CD19靶向治疗后长期疾病控制的主要挑战,CD19和CD22双重靶向已被提出,用作潜在的解决方案。2016年3月-2018年1月,研究人员开展一项研究,纳入了89位难治性/复发性B细胞恶性肿瘤患者,以评估序贯输注抗CD19和抗CD22的双单特异性三代嵌合抗原受体(CAR19/22)-T细胞“鸡尾酒”疗法的疗效和安全性。

中心点:

给难治性/复发性B细胞恶性肿瘤患者序贯输注CAR19/22 T细胞,活性高,且耐受性良好。

双重靶向CD19和CD22或可用于减少CD19/CD22靶向治疗后抗原逃逸复发。

摘要:

抗原逃逸复发已成为CD19靶向治疗后长期疾病控制的主要挑战,CD19和CD22双重靶向已被提出,用作潜在的解决方案。2016年3月-2018年1月,研究人员开展一项研究,纳入了89位难治性/复发性B细胞恶性肿瘤患者,以评估序贯输注抗CD19和抗CD22的双单特异性三代嵌合抗原受体(CAR19/22)-T细胞“鸡尾酒”疗法的疗效和安全性。

51位急性淋巴细胞白血病患者的微小残留病灶阴性反应率为96.0%(95% CI 86.3-99.5)。中位随访16.7个月(1.3-3.3),中位无进展生存期(PFS)为13.6个月(95% CI 6.5-未达到),中位总体存活期(OS)为31.0个月(95% CI 10.6-未达到)。

38位非霍奇金淋巴瘤的总体缓解率为72.2%(95% CI 54.8-85.8),完全缓解率为50%。中位随访14.4个月(0.4-27.4),中位PFS为9.9个月(95% CI 3.3-未达到)。中位OS为18.0个月(95% CI 6.1-未达到)。

随访期间,一位患者发生抗原丢失复发。高级别细胞因子释放综合征和神经毒性的发生率分别为22.4%和1.12%。除了一例,其他均可逆转。

综上所述,本研究表明给B细胞恶性肿瘤患者序贯输注CAR19/22 T细胞安全有效,而且还可降低抗原逃逸复发的发生率。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781580, encodeId=2ba71e81580f6, content=<a href='/topic/show?id=d55c40e812' target=_blank style='color:#2F92EE;'>#CAR19/22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4078, encryptionId=d55c40e812, topicName=CAR19/22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 14:49:00 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273328, encodeId=668e12e33284e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506217, encodeId=ebfb150621e3f, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623353, encodeId=04851623353da, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781580, encodeId=2ba71e81580f6, content=<a href='/topic/show?id=d55c40e812' target=_blank style='color:#2F92EE;'>#CAR19/22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4078, encryptionId=d55c40e812, topicName=CAR19/22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 14:49:00 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273328, encodeId=668e12e33284e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506217, encodeId=ebfb150621e3f, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623353, encodeId=04851623353da, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781580, encodeId=2ba71e81580f6, content=<a href='/topic/show?id=d55c40e812' target=_blank style='color:#2F92EE;'>#CAR19/22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4078, encryptionId=d55c40e812, topicName=CAR19/22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 14:49:00 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273328, encodeId=668e12e33284e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506217, encodeId=ebfb150621e3f, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623353, encodeId=04851623353da, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781580, encodeId=2ba71e81580f6, content=<a href='/topic/show?id=d55c40e812' target=_blank style='color:#2F92EE;'>#CAR19/22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4078, encryptionId=d55c40e812, topicName=CAR19/22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 14 14:49:00 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273328, encodeId=668e12e33284e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506217, encodeId=ebfb150621e3f, content=<a href='/topic/show?id=dcc7384545' target=_blank style='color:#2F92EE;'>#B细胞恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3845, encryptionId=dcc7384545, topicName=B细胞恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55409728490, createdName=chenzhuanggui, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623353, encodeId=04851623353da, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Nov 03 08:49:00 CST 2019, time=2019-11-03, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map